|Dr. Vicente J. Anido Jr.||CEO & Chairman||1.32M||N/A||1953|
|Mr. Thomas A. Mitro||Pres & COO||747.68k||N/A||1958|
|Dr. Casey C. Kopczynski||Co-Founder & Chief Scientific Officer||665.58k||N/A||1961|
|Mr. John W. LaRocca Esq.||Gen. Counsel & Assistant Sec.||658.86k||N/A||1965|
|Dr. David A. Hollander M.B.A., M.D.||Chief R&D Officer||648.77k||N/A||1974|
|Mr. Christopher Staten||Interim Chief Financial Officer||N/A||N/A||1967|
|Mr. Jeffrey Calabrese||Director of Accounting||N/A||N/A||N/A|
|Ms. Ami Bavishi||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Tad Heitmann||VP of Marketing||N/A||N/A||N/A|
|Evan Hockman||VP of Sales||N/A||N/A||N/A|
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Aerie Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2021 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 8; Compensation: 10.